SLNO - CIK 0001484565
The table below shows SOLENO THERAPEUTICS INC's cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | $46.80M | -$69.10M | -$24.94M | -$20.78M | -$27.77M | -$25.22M |
| Capital expenditure | $73.00K | $218.00K | $0.00 | $13.00K | $22.00K | $7.00K |
| Investing cash flow | -$201.78M | -$225.68M | $0.00 | -$13.00K | -$22.00K | -$7.00K |
| Dividends paid | - | - | - | - | - |
SOLENO THERAPEUTICS INC reported operating cash flow of $46.80M for fiscal year 2025. That is up 167.7% from -$69.10M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow grew from -$13.50M (FY 2016) to $46.80M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | $100.15M | $0.00 | $0.00 | - | - | - |
| Financing cash flow | $137.16M | $213.03M | $180.02M | $14.09M | -$128.00K | $53.72M |